Trial Profile
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Glaucoma
- Focus Therapeutic Use
- 08 Jan 2016 New trial record